Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Common Shares, par value CHF 0.08 per share
-
Shares outstanding
-
112M
-
Number of holders
-
51
-
Total 13F shares, excl. options
-
28M
-
Shares change
-
+6.67M
-
Total reported value, excl. options
-
$919M
-
Value change
-
+$217M
-
Number of buys
-
36
-
Number of sells
-
-11
-
Price
-
$32.99
Significant Holders of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) as of Q3 2020
55 filings reported holding ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share as of Q3 2020.
ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) has 51 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28M shares
of 112M outstanding shares and own 25.02% of the company stock.
Largest 10 shareholders include FMR LLC (7.67M shares), Redmile Group, LLC (6.35M shares), JPMORGAN CHASE & CO (2.09M shares), BAKER BROS. ADVISORS LP (1.69M shares), Magnetar Financial LLC (1.62M shares), Grosvenor Holdings, L.L.C. (1.52M shares), ALLIANCEBERNSTEIN L.P. (1.3M shares), PRICE T ROWE ASSOCIATES INC /MD/ (719K shares), EVENTIDE ASSET MANAGEMENT, LLC (580K shares), and MPM ONCOLOGY IMPACT MANAGEMENT LP (540K shares).
This table shows the top 51 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.